在长期护理环境中的老年人中使用特拉佐的现实世界:一项回顾性研究
Alessandra Coin1, Alba Malara2, Marianna Noale3
1Geriatrics Division, Department of Medicine (DIMED), Azienda Ospedale Università di Padova, University of Padova, Padova, Italy.
International journal of geriatric psychiatry
|November 1, 2024
概括
特拉佐在长期护理机构 (LTCF) 中有效治疗老年人的烦躁,失眠,抑郁和焦虑. 虽然通常是安全的,但跌倒是本研究中观察到的最常见的副作用.
科学领域:
- 老年医学 老年医学
- 心理药理学 心理药理学
- 临床药房 临床药房
背景情况:
- 特拉佐是一种抗抑郁药,具有多种临床应用.
- 通常用于治疗失眠,行为障碍和老年人焦虑症.
- 本研究重点关注其在长期护理设施 (LTCF) 的使用.
研究的目的:
- 确定在LTCF中给老年人处方特拉佐的原因.
- 为了评估特拉佐在这个人群中的疗效.
- 在LTCFs中识别与特拉佐使用相关的不良事件.
主要方法:
- 涉及老年人 (≥60岁) 在LTCF使用特拉佐的横截面研究.
- 数据是通过对治疗医生的结构化问卷收集的.
- 分析包括参与者的诊断,处方原因,疗效和不良事件.
主要成果:
- 在427名参与者中,Trazodone被处方用于激动,失眠,抑郁和焦虑.
- 超过90%的参与者表现出部分或全部的效果与特拉佐.
- 跌倒是最常见的不良事件,报告在30%的参与者.
结论:
- 在临床实践中,特拉佐作为一种有效的复杂抗抑郁药而起作用.
- 它对老年患者的痴呆症 (BPSD) 和失眠的行为和心理症状有好处.
- 对特拉佐在老年护理中的作用进行进一步研究是有必要的.
相关概念视频
Antidepressant Drugs: MAOIs and Other Agents
196
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
196
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
317
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
317
Sedatives and Hypnotics Drugs: Miscellaneous Agents
146
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
146
Substance Use Disorders Affecting Sleep
160
Substance use disorders involve a pattern of using drugs more extensively than intended and continuing use despite harmful consequences. This includes legal substances like alcohol and nicotine, as well as illegal drugs. These disorders often involve both physical and psychological dependence, reflecting compulsive use of substances that significantly alter thoughts, feelings, and behaviors, contributing to a major public health issue.
Understanding the concepts of physical dependence,...
Understanding the concepts of physical dependence,...
160
Management of Insomnia
231
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
231
Alzheimer's Disease: Treatment
165
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165


